Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptors blockers

Current Topics in Medicinal Chemistry

Volumn 4, Issue 4, 2004, Pages 483-486

  Marathias, K P ^b   Agroyannis, B ^a   Mavromoustakos, T ^c   Matsoukas, J ^d   Vlahakos, D V ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; FENOTEROL; IRON DERIVATIVE; LOSARTAN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CELL ACTIVATION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HEART FAILURE; HEMATOCRIT; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOXEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; POLYCYTHEMIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATOCRIT; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 3042767460     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451311     Document Type: Review

References (37)

1. Gagnon, D.R.; Zhang T.J.; Brand F.N.; Kannel W.B. Hematocrit and the risk od cardiovascular disease - the Framingham study: a 34-year follow-up. Am. Heart J. 1994, 127, 674-82.
2. Brown D.W.; Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am. Heart J. 2001, 142, 657-63.
3. Brunner, H.R.; Laragh, J.H.; Baer, L.; Newton, M.A.; Goodwin, F.T.; Krakoff, L.R.; Bard, R.H.; Buhler, F.R. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 1972, 286(9), 441-9.
4. Russell, G.I.; Bing, R.F.; Thurston, H.; Swales, J.D. Plasma renin in hypertensive patients: significance in relation to clinical and other biochemical features. Q. J. Med. 1980, 49(195), 385-94.
5. Pagel, H.; Jelkmann, W.; Weiss, C. A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin. Pflugers Arch. 1988, 413, 62-66.
6. Abbrecht, P.H.; Malvin, R.L.; Vander, A.J. Renal production of erythropoietin and renin after experimental kidney infarction. Nature 1966, 211, 1318-19.
7. Chien, S. Blood theology in hypertension and cardiovascular diseaseBCardiovase Med 1977, 2, 356-360.
8. Bourgoignie, J.J.; Gallagher, N.I.; Perry, H.M.; Kurz, L.; Warnecke, M.A.; Donati, R.M. Renin and erythropoietin in normotensive and in hypertensive patients. J. Lab. Clin. Med. 1968, 71, 523-36.
9. Vlahakos, D.V.; Kosmas, E.N.; Dimopoulou, I.; Ikonomou, E.; Jullien, G.; Vassilakos, P.; Marathias, K.P. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am. J. Med. 1999, 106, 158-64.
10. Volpe, M.; Tritto, C.; Testa, U.; Rao, M.A.E.; Martucci, R.; Mirante, A.; Enea, I.; Russo, R,; Rubattu, S.; Condorelli, G.; Cangianiello, S.; Trimarco, B.; Peschle, C.; Condorelli, M. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profile. Am. J. Cardiol. 1994, 74, 468-73.
11. Vlahakos, D.V.; Canzanello, V.J.; Madaio, M.P.; Madias, N.E. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am. J. Kidney Dis. 1991, 17, 199-205.
12. Danovitch, G.M.; Jamgotchian, N.J.; Eggena, P.H.; Paul, W.; Barrett, J.D.; Wilkinson, A.; Lee, D.B.N. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995, 60, 132-37.
13. Julian, B.A.; Brantley, R.R. Jr.; Barker, C.V.; Stopka, T.; Gaston, R.S.; Curtis, J.J.; Lee, J.Y.; Prchal, J.T. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J. Am. Soc. Nephrol. 1998, 9, 1104-8.
14. American Hospital Formulary Service: Drug Information 1988, Bethesda, MD, American Society of Hospital Pharmasists, 1988; p.906.
15. Hirakata, H.; Onoyama, K.; Hori, K.; Fujishima, M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin. Nephrol. 1986, 26(1), 27-32
16. Matsumura, M.; Nomura, H.; Koni, I.; Mabuchi, H. Angiotensin-Converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of cardiac disease in dialysis patients study group. Nephron 1997, 77(2), 164-68.
17. Shand, B.I.; Baily, R.R.; Lynn, K.L.; Robson, R.A. Effect of enalapril on erythrocytosis in hypertensive patients with renal disease. Blood Press 1995, 4, 238-40.
18. Silverberg, D.; Wexler, D.; Sheps, D.; Blum, M.; Keren, G.; Baruch, R.; Schwartz, D.; Yachnin, T.; Steinbruch, S.; Shapira, I.; Laniado, S.; Iaina, A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomised controlled study. J. Am. Coll. Cardiol. 2001, 37, 1775-80.
19. Vlahakos, D.V.; Marathias, K.P.; Kosmas, E.N. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann. Intern. Med. 2001, 134(5), 426-7.
20. Plata, R.; Cornejo, A.; Arratia, C.; Anabaya, A.; Perna, A.; Dimitrov, B.D.; Remuzzi, G.; Ruggenenti, P. Angiotensin-converting enzyme inhibition therapy in altitude polycythemia: a prospective randomised trial. Lancet 2002, 359, 663-66.
21. Vlahakos, D.V.; Marathias, P.K.; Agroyannis, B.; and Madias, N.E. Posttransplant erythrocytosis. Kidney Int. 2003, 63, 1187-94.
22. Anagnostou, A.; Baranowski, R.; Pillay, V.K.G.; Kurtzman, N.; Versellotti, G.; Frei, W. Effect of renin on extrarenal erythropoietin production. J. Lab. Clin. Med. 1976, 88, 707-15.
23. Gould, A.B.; Goodman, B.A.; Green, D. An in vivo effect on erythropoietin formation. Lab. Invest. 1973, 28, 719-22.
24. Freid, W.; Barone-Varelas, J.; Barone, T.; Anagnostou, A. Effect of angiotensin infusion on extrarenal erythropoietin production. J. Lab. Clin. Med. 1982, 99, 520-25.
25. Nakao, K.; Shirakura, T.; Azuma, M.; Mackawa, T. Studies on erythropoietin action of angiotensin II. Blood 1967, 29, 754-60.
26. Gould, A.B.; Goodman, B.A.; DeWolf, R.; Onesti, G.; Swartz, C. Interrelation of the renin system and erythropoietin in rats. J. Lab. Clin. Med. 1980, 96 523-34.
27. Gossmann, J.; Burkhardt, R.; Harder, S.; Lenz, T.; Sedlmeyer, A.; Klinkhardt, U.; Geiger, H.; Scheuermann, E.H. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int. 2001, 60, 83-6.
28. Vlahakos, D.V.; Balodimos, C.; Papachristopoulos, V.; Vassilakos, P.; Hinari, E.; Vlachojannis, J.G. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin. Nephrol. 1995, 43, 53-9.
29. Freudenthaler, S.M.; Schenck, T.; Lucht, I.; Gleiter, C.H. Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system. J. Clin. Pharmacol. 1999, 48, 631-34.
30. Pratt, M.C.; Lewis-Barned, N.J.; Walker, R.J.; Bailey, R.R.; Shand, B.I.; Livesey, J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br. J. Clin. Pharmacol. 1992, 34, 363-65.
31. Kamper, A.L.; Nielsen, O.J. Effect of enalapril on hemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J. Clin. Lab. Invest. 1990, 50, 611-18.
32. Mrug, M.; Stopka, T.; Julian, B.A.; Prchal, J.F.; Prchal, J.T. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J. Clin. Invest. 1997, 100, 2310-4.
33. Gupta, M.; Miller, B.A.; Ahsan, N.; Ulsh, P.J.; Zhang, M.Y.; Cheung, J.Y.; Yang, H.C. Expression of angiotensin II type I receptor on erythroid progenitors of patients with posttransplant erythrocytosis. Transplantation 2000, 70, 1188-94.
34. Yanase, T.; Maki, T.; Nawata, H.; Kato, K.; Ibayashi, H. Effect of angiotensin II on secretion of adrenal androgens. Endocrinol. Jpn. 1984, 31, 741-7.
35. Morrone, L.F.; Di Paolo, S.; Logoluso, F.; Schena, A.; Stallone, G.; Giorgino, F.; Schena, F.P. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997, 64, 913-8.
36. Brox, A.G.; Mangel, J.; Hanley, J.A.; St Louis, G.; Mongrain, S.; Gagnon, R.F. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-1 and its binding proteins. Transplantation 1998, 66, 1053-8.
37. Glicklich, D.; Burris, L.; Urban, A.; Tellis, V.; Greenstein, S.; Schechner, R.; Devarajan, P.; Croizat, H. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J. Am. Soc. Nephrol. 2001, 12, 1958-64.